PharmaDeals Review: Latest Articles
All the latest analysis of deal-making activity in the pharmaceutical and biotechnology sector provided by the experts from the PharmaDeals Review.
- Published on: 2008-05-20 Pfizer Continues Its Biologics Focused Deal-Making Pfizer and Five Prime Therapeutics reach agreement for the discovery of antibody targets and novel therapeutic protein products to treat cancer and diabetes.
- Published on: 2008-05-16 Antisoma's Shares Rise as Company Announces Acquisition of Xanthus UK cancer biotech Antisoma is to acquire private US company Xanthus Pharmaceuticals, which develops small molecule cancer and autoimmune disorder therapeutics. The all-share deal values Xanthus at £26.8 million ($52.2 million).
- Published on: 2008-05-13 Needle-free Vaccines Lead Intercell to the US with its Latest Acquisition Intercell has turned to the US to acquire Iomai - a company that will expand its travellers vaccine franchise and deliver novel transcutaneous immunization technology.
- Published on: 2008-05-13 KAI Pharmaceuticals' Candidate Get Second Chance BMS has entered into a licensing agreement for KAI Pharmaceuticals' KAI-9803, a first-in-class drug being developed to reduce the effects of a heart attack. This deal is examined in light of a previous deal for the drug with Sankyo, which was subsequently terminated.
- Published on: 2008-05-12 Ranbaxy and Merck & Co. Team Up To Develop Novel Anti-Infectives Merck & Co entered into an agreement with Ranbaxy Laboratories to develop clinically validated anti-bacterial and anti-fungal drug candidates.
- Published on: 2008-05-01 Sepracor Enters into Multiple Deals with Arrow Sepracor entered into three deals with Arrow Group and settles patent dispute.
- Published on: 2008-04-24 Dyax and Cubist Sign Deal for DX-88 Surgical Indications This article discusses Dyax and Cubist Pharmaceuticals’ recent deal for Dyax’s DX-88 (ecallantide), a Phase II product for the prevention of blood loss during surgery in North America and Europe.
- Published on: 2008-04-24 Astellas and CoMentis Enter into Deal for Novel Alzheimer's Drug Astellas has entered into a deal to build up its CNS pipeline by licensing CoMentis’ beta-secretase inhibitor programme for Alzheimer's disease.
- Published on: 2008-04-23 GSK Enters into Sirtuin Field with Latest Acquisition GlaxoSmithKline's acquisition of Sirtris Pharmaceuticals is covered. An outline of the novelty of Sirtris' technology is provided, along with a discussion of its potential and the position of Sirtris' rivals after this acquisition.
- Published on: 2008-04-17 Regulus' microRNA Proves Attractive to GSK GSK is another big pharma looking at the potential of RNAi technologies in this deal with Regulus.
Last Issue PDF
RSS